- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06338670
Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users (RECONNECT)
March 24, 2024 updated by: Cochlear
A Pre-market, Feasibility, Prospective, Open-label, Within Subject Investigation Evaluating the Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Recipients
This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant.
Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Therese Agat
- Phone Number: +46766498562
- Email: tagat@cochlear.com
Study Contact Backup
- Name: Christiane L D´hondt
- Phone Number: +32487167531
- Email: cdhondt@cochlear.com
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3053
- The HEARing CRC
-
Contact:
- Robert Cowan
- Phone Number: +61418780198
- Email: r.cowan@unimelb.edu.au
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Implanted with a Cochlear Osia Implant (OSI100 or OSI200)
- Conductive or mixed hearing loss in the implanted ear. Bone conduction threshold 4-frequency pure tone average (PTA4; mean of bone conduction thresholds at 0.5, 1, 2 and 4 kHz) ≤ 55 dB HL.
OR Single-Sided Deafness in the implanted ear. Air Conduction threshold 4-frequency pure tone average (PTA4; mean of air conduction thresholds at 0.5, 1, 2 and 3 kHz) ≤ 20 dB HL in the good ear.
- Aged 18 years or older, at time of consent.
- Minimum experience of 1 month with the Osia 2 Sound Processor.
- Fluent speaker in the language used to assess speech perception performance.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Sensitivity to loud sounds.
- Ongoing infection at or around the sound processor area.
- Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
- Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cochlear™ Osia® System
Participants will receive the Osia 3 and Osia® 2 sound processors.
They will then complete a series of assessments designed to evaluate the clinical performance of these two sound processors.
These assessments will take place across four study visits.
|
Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
Osia® 2 Sound Processor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change (within subject) in speech reception threshold in noise with fixed noise level at 65 dB SPL
Time Frame: During week 24-26
|
Speech perception in noise will be measured using the Australian Speech Test in Noise (AuSTIN), which is a test that uses Bamford-Kowal-Bench (BKB)-like target sentences presented in adaptive noise.
The AuSTIN corpus comprises 80 lists of 20 sentences each, recorded in female voice.
The goal of the adaptive Speech-in-Noise test is to obtain the Speech Reception Threshold in noise.
|
During week 24-26
|
Change (within subject) in word recognition score in quiet measured at 65 dB SPL
Time Frame: During week 24-26
|
Speech perception in quiet will be measured using the consonant-nucleus-consonant (CNC) monosyllabic words presented at 65 dB SPL from the front speaker.
The goal of speech perception assessment in quiet is to obtain the percentage of correctly repeated words in a list, i.e., the word recognition score.
|
During week 24-26
|
Change (within subject) in aided thresholds in sound field measured at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz
Time Frame: During week 24-26
|
Aided thresholds in sound field will be measured using warble tones presented from a front speaker positioned at 1 m from the subject following the modified Hughson-Westlake procedure.
Frequencies to be tested are 250, 500, 750, 1000, 1500, 2000, 3000, 4000, 6000 and 8000 Hz.
|
During week 24-26
|
Change (within subject) in the subjective rating of different aspects of sound when listening to sound clips
Time Frame: During week 24-26
|
After listening to different sound clips with Osia 3 and the Osia 2 sound processors, the subjects will rate specific aspects of the sound, e.g., loudness or sound quality, on a Likert scale from 1 to 5 in steps of 1.
A rating of 1 is least positive while a rating of 5 is most positive.
They will also be asked to explain their sound quality experience in their own words per sound clip.
|
During week 24-26
|
Percentage of participants who preferred Osia 3 over Osia 2 sound processor
Time Frame: During week 24-26
|
Participants will be asked which device they prefer after having listened with both devices (Osia 2 and Osia 3) to different sound clips.
|
During week 24-26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 8, 2024
Primary Completion (Estimated)
November 22, 2024
Study Completion (Estimated)
November 22, 2024
Study Registration Dates
First Submitted
March 24, 2024
First Submitted That Met QC Criteria
March 24, 2024
First Posted (Actual)
March 29, 2024
Study Record Updates
Last Update Posted (Actual)
March 29, 2024
Last Update Submitted That Met QC Criteria
March 24, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLTD5839
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Cochlear do not have an approved platform for public sharing of IPD collected in this study.
Data may be provided to individual researchers on request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss, Conductive
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
Oticon MedicalSahlgrenska University Hospital, SwedenCompletedConductive Hearing Loss | Mixed Hearing LossSweden
-
Audioptics Medical IncorporatedNot yet recruitingConductive Hearing Loss, Middle Ear
-
Oticon MedicalActive, not recruitingConductive Hearing Loss | Mixed Hearing LossSweden
-
Oticon MedicalCompletedConductive Hearing Loss | Mixed Hearing Loss | Unilateral Partial DeafnessSweden
-
Oticon MedicalCompletedConductive Hearing Loss | Unilateral Partial Deafness | Mixed Conductive-sensorineural Hearing LossNetherlands
-
Khon Kaen UniversityPrince of Songkla University; Chiang Mai UniversityNot yet recruitingNormal Hearing | Conductive Hearing Loss, Middle EarThailand
-
CochlearCompletedConductive Hearing Loss | Deafness; Sensoneural Single Sided | Mixed Hearing LossUnited States, Netherlands, Australia, Germany, Poland
-
CochlearCompletedConductive Hearing Loss | Deafness; Sensoneural Single Sided | Mixed Hearing LossAustralia
Clinical Trials on Cochlear Osia 3 Sound Processor
-
Advanced BionicsCompletedOtorhinolaryngologic Diseases | Ear Diseases | Hearing Loss | Hearing DisordersUnited States
-
CochlearCompletedHearing LossUnited States
-
Fundación Pública Andaluza para la gestión de la...RecruitingBilateral Sensorineural Hearing Loss | Unilateral Sensorineural Hearing LossSpain
-
CochlearCompletedHearing LossBelgium, Australia
-
CochlearAvania; QbD ClinicalRecruitingHearing LossBelgium, United Kingdom, Italy, Netherlands
-
CochlearAvaniaCompleted
-
CochlearAvaniaCompletedAdult Cochlear Implant RecipientsAustralia
-
Oticon MedicalSahlgrenska University Hospital, SwedenCompletedConductive Hearing Loss | Mixed Hearing LossSweden
-
Advanced Bionics AGCompletedCochlear Hearing LossGermany